This excerpt taken from the BMY 8-K filed Apr 28, 2005.



Bristol-Myers Squibb obtained its fourth new drug approval in just two and a half years when, in March 2005, the Food and Drug Administration approved BARACLUDE® (entecavir) for treatment of chronic hepatitis B infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.


“We were pleased by the FDA’s approval of BARACLUDE® following the unanimous recommendation of the Antiviral Drugs Advisory Committee and we are in regulatory reviews with FDA on muraglitazar and abatacept,” said Elliott Sigal, M.D., Ph.D., chief scientific officer and president of the Bristol Myers Squibb Pharmaceutical Research Institute. “First quarter progress in our pipeline was also demonstrated by FDA approval of a new ABILIFY® indication for maintaining efficacy in patients with Bipolar I Disorder, as well as the results of the ‘CLARITY’ and ‘COMMIT’ trials for PLAVIX®.”


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki